Marine Macroalga-associated <i>Bacillus amyloliquefaciens</i> as Prospective Probiotic

Heterotrophic Bacillus amyloliquefaciens (MTCC 12716) isolated from the red alga Hypnea valentiae exhibited promising antibacterial activity (minimum inhibitory concentration of ≤1.0 µg/mL) against clinically relevant pathogens. The bacterium displayed bile salt and acid tolerance up to 4 h in a simulated gastric fluid, along with prospective antioxidant effect. This non-hemolytic was found be sensitive panel antibiotics did not amplify enterotoxin-specific genes. In order analyze possibilities scaling up, we have optimized growth B. by response surface methodology realize maximum production anti-infective agents fermentation medium observed an increment about 85% gastrointestinal As probiotic treatment is useful due its ability recreate natural intestinal microflora, this heterotrophic could contemplated offer probiotic. Further studies are needed assess utility for commercial application.